article thumbnail

Becerra’s Vote for Drug Importation in 2003

Policy Prescription

Becerra (D-CA) voted for the “Canadian drug importation law” in 2003. And that gets us back to former Congressman Becerra’s vote in 2003. He voted for the Pharmaceutical Market Access Act of 2003, H.R. The post Becerra’s Vote for Drug Importation in 2003 appeared first on Policy Prescription. Congratulations!

Drugs 52
article thumbnail

Atlas Venture 2023 Year In Review

LifeSciVC

2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. We then shift to the venture ecosystem and the broader capital markets, highlighting the parallels with twenty years ago, post the genomics bubble in 2002-2003.

Science 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biotech Venture Ecosystem: Quick Health Check

LifeSciVC

Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With a little over 50 new startups raising capital in 4Q24, we’re back to levels not seen for nearly a decade, at the start of the biotech secular bull market in 2013-2014.

Marketing 112
article thumbnail

Biotech Consolidation: Not Really Happening

LifeSciVC

Several years into the post-bubble bear market, the public biotech sector has only contracted by 4.5% Here are the data from BMO Capital Markets, looking at the changes to the overall public market company counts: Shutdowns were only 2% of the sector: declaring failure and closing up shop just hasn’t happened often.

Marketing 111
article thumbnail

A personal view on antibody drug development

Drug Discovery World

Time will tell which of those many new modalities prove worthy of a marketing approval. Dr Schon obtained his PhD in Cancer Research from The University of Cambridge before joining Sir Greg Winter’s biotech venture Domantis in 2003 which was acquired by GSK three years later.

article thumbnail

Kickstarting the use of AI for biotechs: part one

Drug Target Review

The latter group (ie, most of us) are waiting for wet lab validation, market demonstration (FDA approvals), and a few other things (which we often cannot define). Crossing the Chasm: Marketing and Selling high-tech Products to Mainstream Customers. Drug Discovery & Development. 20 biotech startups attracted almost $3B in Q1 2024.

article thumbnail

Kickstarting the use of AI for biotechs: part three

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Science 63